Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine plus melphalan as conditioning for autologous HSCT in multiple myeloma
ChiCTR2100048305Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine and melphalan in multiple myeloma (MM), sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete remission and above remission rate at 100 days post-transplant. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
bendamustinemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100048305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048305.